Nventa Biopharmaceuticals Corp., of San Diego, received U.S. Patent No. 7,211,411 B2, covering the use of HspE7, the company's therapeutic vaccine for human papillomavirus (HPV)-related diseases. The patent covers a method of treating patients with anogenital warts using a fusion protein comprised of a heat-shock protein from the Hsp60 family and an HPV E7 antigen.

Oncolytics Biotech Inc., of Calgary, was granted U.S. Patent No. 7,186,542, titled "Method of Extracting Virus from Cell Culture," covering a method of producing infectious reovirus that allows for the removal of cell debris by filtration and concentration of the filtrate. The company also received U.S. Patent No. 7,198,783, titled "Sensitization of Neoplastic Cells to Radiation Therapy with Reovirus." That patent describes a method of using reovirus to sensitize Ras-activated cancer cells that are resistant to radiation therapy.

Osprey Pharmaceuticals Ltd., of Montreal, was granted three patents relating to its Leukocyte Population Modulator platform: U.S. Patent No. 7,157,418, titled "Methods and Compositions for Treating Secondary Tissue Damage and Other Inflammatory Conditions and Disorders," U.S. Patent No. 7,166,702, titled "Cytotoxic Conjugates Comprising a Chemokine Receptor Targeting Agent," and U.S. Patent No. 7,192,736, titled "Nucleic Acid Molecules Encoding Cytotoxic Conjugates That Contain a Chemokine Receptor Targeting Agent."

Protalex Inc., of New Hope, Pa., received a patent, titled "Protein A Compositions and Methods of Use," which covers the use of the company's lead drug, PRTX-100, in rheumatoid arthritis, juvenile arthritis, lupus and other antibody-mediated acute inflammatory conditions.